liraglutide to semaglutide conversion Spotlight on the Mechanism of Action of The limitation of lipidation: Conversion

The second will take longer to answer: Did a GLP-1 weight-loss drug enhance her performance

#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy To view or add a comment, sign in : Eli Lilly and Company just released Phase 3 ATTAIN-MAINTAIN data on orforglipron, a once daily oral GLP-1 receptor agonist, and I think it speaks directly to one of the most painful realities my patients face: not losing weight, but it - Participants first completed 72 weeks on high-dose injectable semaglutide (Wegovy) or tirzepatide (Zepbound) in SURMOUNT-5, with very large average weight reductions

"GLP-1" is EVERYWHERE

The primary outcome was three major adverse cardiovascular events (MACE) AMI, stroke, and all-cause mortality which showed significantly reduced odds in the GLP-1RA group